维基百科,自由的百科全书
奥来鲁单抗(INN:oleclumab;开发代号:MEDI9447)是一种抗CD73人单克隆抗体,旨在治疗胰腺癌、结直肠癌和其他癌症。[1][2]
该药物由MedImmune/阿斯利康开发。[3]
- ^ ClinicalTrial.gov for Oleclumab
- ^ Bendell, Johanna; LoRusso, Patricia; Overman, Michael; Noonan, Anne M.; Kim, Dong-Wan; Strickler, John H.; Kim, Sang-We; Clarke, Stephen; George, Thomas J.; Grimison, Peter S.; Barve, Minal. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer immunology, immunotherapy: CII. 2023-07, 72 (7) [2024-06-01]. ISSN 1432-0851. PMID 37016126. doi:10.1007/s00262-023-03430-6. (原始内容存档于2024-06-01).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab (页面存档备份,存于互联网档案馆), American Medical Association.